By Ben Hirschler MADRID (Reuters) - It is too early to say whether combining Roche's best-selling Avastin cancer drug with the company's experimental immune-boosting medicine MPDL3280A gives a better outcome in fighting tumors. That is the verdict of experts following a presentation of a small clinical study assessing the combination in patients with a variety of solid tumors. ...
via Health News Headlines - Yahoo News http://ift.tt/YwmLig
No comments:
Post a Comment